The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | How the 5-year data of POLARIX contribute to understanding long-term efficacy of Pola-R-CHP in DLBCL
Krish Patel, MD, Sarah Cannon Cancer Institute, Nashville, TN, comments on how the five-year follow-up data from the POLARIX study (NCT03274492) contribute to the understanding of the long-term efficacy of polatuzumab vedotin (Pola) with R-CHP in diffuse large B-cell lymphoma (DLBCL). Dr Patel emphasizes that adding polatuzumab to frontline therapy improves the chance of cure for a subset of patients and suggests it should be continued to be offered to specific patients. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
So the POLARIX study is presenting longer term follow up at this meeting. I think everybody has been waiting to see that. What we have known for some time is that with a short follow-up of two years that there’s an improvement in progression-free survival with the Pola-R-CHP regimen. Our goal of treatment in large cell lymphoma is really to try to cure patients, and so if we’re seeing that early on, I think the question has been, what is that going to look like at five years? And what we see is that we’ve maintained the same benefit that was present at the two-year follow-up...
So the POLARIX study is presenting longer term follow up at this meeting. I think everybody has been waiting to see that. What we have known for some time is that with a short follow-up of two years that there’s an improvement in progression-free survival with the Pola-R-CHP regimen. Our goal of treatment in large cell lymphoma is really to try to cure patients, and so if we’re seeing that early on, I think the question has been, what is that going to look like at five years? And what we see is that we’ve maintained the same benefit that was present at the two-year follow-up. A lot of questions around overall survival had been raised previously. What we see is there isn’t an overall survival difference. I think that that may reflect the kind of growing number of tools that are available for patients who relapse. So it may be hard to show in an era where we have more and more tools like bispecific antibodies, CAR T-cells, to show that overall survival difference. But for me, I think what it tells us is that adding polatuzumab to frontline therapy does improve our chance of cure for a subset of patients, and we should continue to offer that therapy to the right patients.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Sunesis Pharmaceuticals: Consultancy, Research Funding; CRISPR Therapeutics: Research Funding; Fate Therapeutics: Research Funding; Genentech/Roche: Consultancy, Research Funding; MEI Pharma: Consultancy, Research Funding; Merck: Consultancy, Research Funding; Morphosys: Consultancy; AbbVie: Consultancy; Adaptive Biotechnologies: Research Funding; Nurix: Research Funding; Trillium Therapeutics/Pfizer: Consultancy, Research Funding; Pharmacyclics/Janssen: Consultancy, Research Funding; TG Therapeutics: Consultancy, Speakers Bureau; Kite: Consultancy, Research Funding, Speakers Bureau; Loxo Oncology: Consultancy, Research Funding; Epizyme: Consultancy, Research Funding; Curis, Inc: Research Funding; AstraZeneca: Consultancy, Research Funding, Speakers Bureau; ADC Therapeutics: Consultancy; Xencor: Consultancy, Research Funding; BeiGene: Consultancy; Bristol Myers Squibb: Consultancy, Research Funding, Speakers Bureau; Caribou Biosciences: Consultancy.
